Atezolizumab

Active ingredient description

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01FF05
Atezolizumab
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF05

Medicines

Atezolizumab is the active ingredient of these drugs:

Drug
Countries
TECENTRIQ

Australia Austria Brazil Canada Cyprus

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
TECENTRIQ Concentrate for solution for infusion
Summary of product characteristics (SPC)

Unique ingredient identifier (UNII)

52CMI0WC3Y - ATEZOLIZUMAB

SNOMED-CT

719371003 - Atezolizumab (substance)

Next: Usage